Physician profile
Darshan Patel
NPI 1427513571
$2,071.17
in general payments reported to CMS, 2019-2025
21 companies · $300 in 2025
The $300 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $521 · 2022: $506 · 2023: $469 · 2024: $276 · 2025: $300.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,045.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,044.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $259.37 | 2021-2025 | Trelegy Ellipta, Nucala |
| Takeda Pharmaceuticals U.S.A., INC. | $250.44 | 2021-2025 | Eohilia, Cuvitru, Takhzyro |
| Regeneron Healthcare Solutions, INC. | $241.83 | 2021-2025 | Dupixent |
| Csl Behring | $221.66 | 2021-2025 | Haegarda, Hizentra, Andembry |
| Optinose US, INC. | $147.67 | 2021-2025 | |
| Amgen INC. | $147.18 | 2022-2024 | Tezspire |
| Kaleo, INC. | $116.23 | 2021-2024 | Auvi-Q |
| Genzyme Corporation | $95.46 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $80.07 | 2021-2023 | Fasenra |
| Grifols USA, LLC | $76.60 | 2021-2023 | Xembify |
| Genentech USA, INC. | $72.81 | 2022-2024 | Xolair |
| Alk-Abello, INC | $50.26 | 2022-2023 | Pre-Pen, Alternaria Tenuis, Histamine Positive |
| Incyte Corporation | $48.33 | 2022-2023 | Opzelura |
| Boehringer Ingelheim Pharmaceuticals, INC. | $46.90 | 2021 | |
| Biocryst US Sales Co., LLC | $41.98 | 2021-2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $40.25 | 2022 | |
| Pharming Healthcare, INC. | $36.52 | 2023-2024 | Ruconest |
| Organon LLC | $30.47 | 2025 | |
| Novartis Pharmaceuticals Corporation | $30.35 | 2025 | |
| Paratek Pharmaceuticals, INC. | $20.62 | 2025 | Xhance |
| Aimmune Therapeutics, INC. | $16.17 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Darshan Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.